In 2008, the SHARP trial established sorafenib, which simultaneously inhibits tumor growth by targeting the Raf-MEK-ERK cascade as well as angiogenesis by targeting vascular endothelial growth factor (VEGFR) 2, platelet-derived growth factor receptors (PDGFR) and KIT as a novel standard treatment in patients with advanced HCC (9). The gene discussed is KIT; the disease is hepatocellular carcinoma.